News & Updates

Johnson Matthey Catalysis & Chiral Technologies has achieved a significant breakthrough in phosphine catalyst technology, introducing a new generation of pi-allyl palladium catalysts that deliver unprecedented results in pharmaceutical synthesis.

The new catalyst system demonstrates exceptional selectivity and efficiency in complex molecular transformations, particularly in the synthesis of active pharmaceutical ingredients (APIs) where precision is crucial.

"This represents a major step forward in our mission to provide the most advanced catalytic solutions to the pharmaceutical industry," said Dr. Sarah Martinez, Head of Catalyst Development. "The improved selectivity reduces side reactions by up to 85%, significantly improving yield and reducing waste."

Key benefits of the new technology include:

• Enhanced selectivity for challenging pharmaceutical intermediates
• Reduced catalyst loading requirements
• Improved stability under reaction conditions
• Compatibility with a broader range of substrates

The catalyst is now available through our product catalog and represents our commitment to innovation in sustainable chemistry solutions.

Johnson Matthey Catalysis & Chiral Technologies has been honored with the prestigious Green Chemistry Innovation Award for 2024, recognizing our groundbreaking work in developing sustainable biocatalyst solutions.

The award acknowledges our comprehensive approach to reducing environmental impact through the development of enzymatic catalysts that operate under mild conditions and eliminate the need for toxic solvents.

"This recognition validates our commitment to developing catalytic solutions that not only meet industry needs but also contribute to a more sustainable future," commented Dr. Michael Chen, Director of Sustainability.

Our recent achievements include:

• Development of thermostable enzymes for industrial applications
• Creation of cascade reaction systems reducing process steps by 40%
• Implementation of biocatalytic processes eliminating heavy metal usage
• Collaboration with pharmaceutical companies on green API synthesis

The award ceremony will take place at the International Conference on Green Chemistry in Boston, March 2025.

Johnson Matthey Catalysis & Chiral Technologies has officially opened its new manufacturing facility in Singapore, marking a significant expansion of our Asian operations to better serve the rapidly growing pharmaceutical and fine chemical markets in the region.

The 50,000 square foot facility features advanced production capabilities for heterogeneous and homogeneous catalysts, with particular focus on chiral catalyst manufacturing for the pharmaceutical industry.

"This facility represents our commitment to providing local support and faster delivery to our Asian customers," said James Wilson, Vice President of Operations. "We're excited to bring our world-class manufacturing capabilities closer to this important market."

Facility highlights include:

• Clean room manufacturing suites for pharmaceutical-grade catalysts
• Advanced analytical laboratories for quality control
• Pilot plant facilities for customer development work
• Capacity to produce over 1,000 metric tons of catalysts annually

The facility is expected to create over 150 new jobs in the region and will serve customers across Asia-Pacific, with particular focus on pharmaceutical manufacturers in India, China, and Southeast Asia.

Johnson Matthey Catalysis & Chiral Technologies announces strategic collaborations with several leading pharmaceutical companies to advance catalyst development for next-generation drug synthesis challenges.

These partnerships focus on developing innovative catalytic solutions for complex molecular transformations required in the synthesis of novel therapeutic compounds, particularly in oncology and rare disease treatments.

"Collaboration with our pharmaceutical partners is essential to understanding their evolving needs and developing solutions that address real-world challenges," stated Dr. Emma Rodriguez, Head of Pharmaceutical Partnerships.

Key collaboration areas include:

• Development of catalysts for complex natural product synthesis
• Chiral catalyst systems for enantioselective transformations
• Flow chemistry applications for continuous manufacturing
• Biocatalytic processes for sustainable API production

These partnerships are expected to result in breakthrough technologies that will be made available to the broader pharmaceutical industry through our standard product offerings.

Johnson Matthey Catalysis & Chiral Technologies has inaugurated a new advanced catalyst characterization laboratory at our West Deptford facility, significantly enhancing our analytical capabilities for catalyst development and optimization.

The laboratory features cutting-edge instrumentation for comprehensive catalyst analysis, including surface area analysis, pore structure determination, and in-situ reaction monitoring capabilities.

"This investment in analytical infrastructure allows us to better understand catalyst behavior and optimize performance for specific customer applications," explained Dr. Alan Thompson, Director of Analytical Sciences.

Laboratory capabilities include:

• High-resolution electron microscopy for catalyst morphology analysis
• X-ray photoelectron spectroscopy for surface composition studies
• In-situ FTIR spectroscopy for reaction mechanism elucidation
• Automated catalyst testing systems for high-throughput screening

The facility will support both internal R&D activities and customer-specific development projects, ensuring we can deliver optimized catalytic solutions for the most demanding applications.

Johnson Matthey Catalysis & Chiral Technologies has successfully implemented a comprehensive Industry 4.0 initiative across our manufacturing operations, incorporating advanced digital technologies to enhance production efficiency and quality control.

The digital transformation includes implementation of IoT sensors, machine learning algorithms for predictive maintenance, and real-time quality monitoring systems throughout our production facilities.

"Digital transformation is essential for maintaining our competitive edge and ensuring we can meet the evolving needs of our customers," said Lisa Parker, Chief Technology Officer.

Key digital initiatives include:

• Real-time process monitoring with AI-powered analytics
• Predictive maintenance systems reducing downtime by 30%
• Digital twin technology for process optimization
• Automated quality control systems with machine learning

These improvements have resulted in significant enhancements to production efficiency, product quality, and customer service levels across all our manufacturing facilities.

Johnson Matthey Catalysis & Chiral Technologies has launched a new catalyst sample kit program designed to accelerate customer development timelines and reduce time-to-market for new pharmaceutical products.

The program offers carefully curated sample kits containing our most popular catalyst types, allowing customers to quickly evaluate performance in their specific applications without the need for individual catalyst requests.

"Our sample kit program addresses a key customer need by providing immediate access to a broad range of catalyst options," commented Dr. Jennifer Walsh, Head of Customer Development.

Available sample kits include:

• Heterogeneous catalyst screening kit (40 different catalysts)
• Chiral catalyst development kit for enantioselective synthesis
• Biocatalyst evaluation kit for sustainable chemistry applications
• Specialty catalyst kit for complex pharmaceutical transformations

Each kit includes comprehensive technical documentation, application notes, and direct access to our technical support team for guidance and optimization assistance.

Johnson Matthey Catalysis & Chiral Technologies has entered into a strategic research partnership with the Massachusetts Institute of Technology (MIT) to develop next-generation catalyst technologies for sustainable chemistry applications.

The three-year collaboration will focus on fundamental research into novel catalyst designs that could revolutionize efficiency and selectivity in pharmaceutical and fine chemical synthesis.

"This partnership brings together MIT's world-class research capabilities with our deep industry expertise to tackle some of the most challenging problems in catalysis," stated Dr. Robert Kim, Vice President of Research.

Research focus areas include:

• Single-atom catalysts for enhanced activity and selectivity
• Machine learning approaches to catalyst design
• Novel support materials for improved catalyst stability
• Sustainable synthesis routes for pharmaceutical intermediates

The partnership is expected to result in breakthrough technologies that will be developed into commercial products over the next five years.

Johnson Matthey Catalysis & Chiral Technologies reports strong quarterly results, with the biocatalyst segment showing particularly robust growth driven by increasing demand for sustainable catalytic solutions.

The biocatalyst division achieved 35% year-over-year growth, reflecting the industry's continued shift toward more sustainable manufacturing processes and our successful development of innovative enzymatic solutions.

"These results demonstrate the market's recognition of the value that biocatalysts bring to pharmaceutical and fine chemical manufacturing," commented CFO David Brown.

Key performance highlights include:

• 35% growth in biocatalyst segment revenue
• Successful launch of five new biocatalyst products
• Expansion of customer base by 25% in the quarter
• Strong demand from pharmaceutical manufacturers in Asia

The company continues to invest heavily in biocatalyst research and development, with plans to expand manufacturing capacity to meet growing demand.

Johnson Matthey Catalysis & Chiral Technologies has received the Innovation Award from the Chemical Industry Association for our outstanding contribution to sustainable catalyst development.

The award recognizes our comprehensive approach to developing catalytic solutions that minimize environmental impact while maintaining superior performance characteristics.

"This recognition validates our belief that sustainability and performance are not mutually exclusive," said Dr. Rachel Green, Head of Sustainable Development.

Award-winning innovations include:

• Development of recyclable catalyst systems
• Creation of solvent-free catalytic processes
• Implementation of renewable feedstock utilization
• Reduction of catalyst waste through improved recovery methods

The award ceremony will be held at the Annual Chemical Industry Conference in Chicago, where we will present our latest developments in sustainable catalysis.